https://www.selleckchem.com/pr....oducts/nazartinib-eg
549-0.825; p 0.001; I = 17.7%). SGLT2i treatment was associated with a lower incidence of serious adverse events (SAEs) (RR 0.867; 95% CI, 0.808-0.930; p 0.001; I = 60.1%), but a higher incidence of volume depletion (RR 1.177; 95% CI, 1.040-1.333; p = 0.010; I = 0.0%). Analysis on patients without DM showed consistent results, except for cardiovascular death. SGLT2i treatment contributed to better cardiovascular and renal outcomes in patients with HF, regardless of the presence or absence of DM. SGLT2i also r
Like
Comment
Share
